Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors

  • Lei, Yuan-Yuan (Department of Pathology, the First Affiliated Hospital of Nanchang University) ;
  • Wang, Wei-Jia (Department of Pathology, the First Affiliated Hospital of Nanchang University) ;
  • Mei, Jin-Hong (Department of Pathology, the First Affiliated Hospital of Nanchang University) ;
  • Wang, Chun-Liang (Department of Neurosurgery, the First Affiliated Hospital of Nanchang University)
  • 발행 : 2014.11.06


Mitogen-activated protein kinase (MAPK) is an important signaling pathway in living beings in response to extracellular stimuli. There are 5 main subgroups manipulating by a set of sequential actions: ERK(ERK1/ERK2), c-Jun N(JNK/SAPK), p38 MAPK($p38{\alpha}$, $p38{\beta}$, $p38{\gamma}$ and $p38{\delta}$), and ERK3/ERK4/ERK5. When stimulated, factors of upstream or downstream change, and by interacting with each other, these groups have long been recognized to be related to multiple biologic processes such as cell proliferation, differentiation, death, migration, invasion and inflammation. However, once abnormally activated, cancer may occur. Several components of the MAPK network have already been proposed as targets in cancer therapy, such as p38, JNK, ERK, MEK, RAF, RAS, and DUSP1. Among them, alteration of the RAS-RAF-MEK-ERK-MAPK(RAS-MAPK) pathway has frequently been reported in human cancer as a result of abnormal activation of receptor tyrosine kinases or gain-of-function mutations in genes. The reported roles of MAPK signaling in apoptotic cell death are controversial, so that further in-depth investigations are needed to address these controversies. Based on an extensive analysis of published data, the goal of this review is to provide an overview on recent studies about the mechanism of MAP kinases, and how it generates certain tumors, as well as related treatments.


연구 과제 주관 기관 : National Natural Science Foundation of China, Natural Science Fundation of Jiangxi Province


  1. Ades F, Metzger-Filho O (2012). Targeting the cellular signaling: BRAF inhibition and beyond for the treatment of metastatic malignant melanoma. Dermatol Res Pract, 2012, 259170.
  2. Ahmad I, Patel Y, Liu L. B, et al (2011). Ras mutation cooperates with beta-catenin activation to drive bladder tumourigenesis. Cell Death Dis, 2, 124.
  3. Bagley M, Davis P, Murziani S, et al (2010). Use of p38 MAPK inhibitors for the treatment of Werner Syndrome. Pharmaceuticals, 3, 1842-72.
  4. Ahn J, Eom C, Jeon S (2013). Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol, 19, 2560-8.
  5. Amankwah E, Sellers T, Park Y (2012). Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis, 33, 1259-69.
  6. Ara T, Declerck Y (2010). Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer, 46, 1223-31.
  7. Bauckman K, Haller E, Flores I, et al (2013). Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. Cell Death Dis, 4, 592.
  8. Bourboulia D, Stetler-Stevenson W (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol, 20, 161-8.
  9. Boyd F, Martin L, Bronskill M, et al (2010). Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst, 102, 1224-37.
  10. Cargnello M, Roux P (2011). Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev, 75, 50-83.
  11. Cerne J, Stegel V, Gersak K, et al (2012). KRAS rs61764370 is associated with HER2-overexpressed and poorlydifferentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer, 12, 105.
  12. Chang E, Yang J, Alfaro-Velcamp T, et al (2010). Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev, 19, 3106-18.
  13. Clarke R, Schirra H, Catto J, et al (2010). Markers for detection of prostate cancer. Cancers, 2, 1125-54.
  14. Chao S, Huang S, et al (2013). Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways. Evid Based Complement Alternat Med, 2013, 817674.
  15. Charles N, Thomas P, Lange C (2010). Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer, 1, 167-76.
  16. Cheng Y, Ueno N (2012). Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer, 19, 191-9.
  17. Coleman R, Monk B, Sood A, et al (2013). Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol, 10, 211-4.
  18. Connolly R, Carducci M, et al (2012). Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl, 14, 177-86.
  19. Curiel-Lewandrowski C, Chen C, Swetter S, et al (2012). Screening and prevention measures for melanoma: is there a survival advantage? Curr Oncol Rep, 14, 458-67.
  20. Cust A, Armstrong B, Goumas C, et al (2011). Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer, 128, 2425-35.
  21. Davies M, Samuels Y (2010). Analysis of the genome to personalize therapy for melanoma. Oncogene, 29, 5545-55.
  22. Mello R, Marques D, Medeiros R, et al (2011). Epidermal growth factor receptor and K-Ras in non-small cell lung cancermolecular pathways involved and targeted therapies. World J Clin Oncol, 2, 367-76.
  23. Dey S, Ghosh N, Saha D, et al (2014). Matrix metalloproteinase-1 (MMP-1) Promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population. PLoS One, 9, 88040.
  24. Dela Cruz C, Tanoue L, et al (2011). Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med, 32, 605-44.
  25. Demaria S, Pikarsky E, Karin M, et al (2010). Cancer and inflammation: promise for biologic therapy. J Immunother, 33, 335-51.
  26. Detchokul S, Frauman A (2011). Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol, 71, 157-74.
  27. Dixon D, Blanco F, Bruno A, et al (2013). Mechanistic aspects of COX-2 expression in colorectal neoplasia. Rec Res Cancer Res, 91, 7-37.
  28. Drake G (2010). Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol, 10, 580-93.
  29. Dudek A, Grotenhuis A, Vermeulen S, et al (2013). Urinary bladder cancer susceptibility markers. what do we know about functional mechanisms? Int J Mol Sci, 14, 12346-66.
  30. Egleston B, Meireles S, Flieder D, et al (2009). Population-based trends in lung cancer incidence in women. Semin Oncol, 36, 506-15.
  31. Evans M, Madhunapantula S, Robertson G, et al (2013). Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol, 779, 223-55.
  32. Falchook G, Lewis K, Infante J, et al (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncology, 13, 782-89.
  33. Galan-Moya E, Cruz-Morcillo M, Llanos Valero M, et al (2011). Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC. PLoS One, 6, 28406.
  34. Grieco L, Calzone L, Bernard-Pierrot I, et al (2013). Integrative modelling of the influence of MAPK network on cancer cell fate decision. PLoS Comput Biol, 9, 1003286.
  35. Gholami S, Chen C, Gao S, Lou E, et al (2014). Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Ther, 21, 283-9.
  36. Gogoi R., Kudla M, Gil O, et al (2008). The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion. Reprod Sci, 15, 846-52.
  37. Gomes L, Terra L, Wailemann R, et al (2012). TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer, 12, 26.
  38. Hassanein M, Callison J, Callaway-Lane C, et al (2012). The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res, 5, 992-1006.
  39. Hollenhorst P, Ferris M, Hull M, et al (2011). Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev, 25, 2147-57.
  40. Inamdar G, Madhunapantula S, et al (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol, 80, 624-37.
  41. Izrailit J, Berman H, Datti K, et al (2013). High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFbeta pathways as fundamental Notch regulators in breast cancer. Proc Natl Acad Sci U S A, 110, 1714-9.
  42. Jeannin P, Duluc D, Delneste Y (2011). IL-6 and leukemiainhibitory factor are involved in the generation of tumorassociated macrophage: regulation by IFN-gamma. Immunotherapy, 3, 23-26.
  43. Jelovac D, Armstrong D (2011). Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin, 61, 183-203.
  44. Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cel, 141, 52-67.
  45. Jia-Qi S, Kun-Peng X, Wei Z (2014). Emodin inhibits breast cancer cell proliferation through the ER$\alpha$-MAPK/Akt-Cyclin D1/Bcl-2 signaling pathway. Asian Pac J Cancer Prev, 15, 6247-51.
  46. Jin J, Dayyani F, Gallick G (2011). Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer, 128, 2545-61.
  47. Kadara H, Kabbout M, Wistuba M (2012). Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology, 17, 50-65.
  48. Khwaja F, Quann E, Pattabiraman N, et al (2008). Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther, 7, 3539-45.
  49. Koh C, Bieberich C, Dang C, et al (2010). MYC and prostate cancer. Genes Cancer, 1, 617-28.
  50. Kohli M, Tindall D (2010). New developments in the medical management of prostate cancer. Mayo Clin Proc, 85, 77-86.
  51. Kompier L, Lurkin I, Aa M, et al (2010). FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One, 5, 13821.
  52. Korner A, Drapeau M, Thombs B, et al (2013). Barriers and facilitators of adherence to medical advice on skin selfexamination during melanoma follow-up care. BMC Dermatol, 13, 3.
  53. Koul H, Pal M, Koul S (2013). Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer, 342-59.
  54. Lamy E, Herz C, Lutz-Bonengel S, et al (2013). The MAPK pathway signals telomerase modulation in response to isothiocyanate-induced DNA damage of human liver cancer cells. PLoS One, 8, 53240.
  55. Li Y, Kong D, Bao B, et al (2011). Induction of cancer cell death by isoflavone: the role of multiple signaling pathways. Nutrients, 3, 877-96.
  56. Larsen J, Cascone T, Gerber D, et al (2011). Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J, 17, 512-27.
  57. Larsen J, Minna J (2011). Molecular biology of lung cancer: clinical implications. Clin Chest Med, 32, 703-40.
  58. Li C, Fan S, Owonikoko T, et al (2011). Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene, 30, 3802-12.
  59. Ligr M, Patwa R, Daniels G, et al (2011). Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. PLoS One, 6, 26250.
  60. Lin K, Baritaki S, Militello L, et al (2010). The role of B-RAF mutations in melanoma and the induction of emt via dysregulation of the NF-kappaB/Snail/RKIP/PTEN circuit. Genes Cancer, 1, 409-20.
  61. Lin L, Deng W, Tian Y, et al (2014). Lasiodin inhibits proliferation of human nasopharyngeal carcinoma cells by simultaneous modulation of the Apaf-1/caspase, AKT/MAPK and COX-2/NF-kappaB signaling pathways. PLoS One, 9, 97799.
  62. Liu H, Wang L, Liu Z, et al (2013). Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. Carcinogenesis, 34, 885-92.
  63. Lofgren K, Ostrander J, et al (2011). Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Res, 13, 89.
  64. Lv Z, Xu L (2012). Salvianolic Acid B Inhibits ERK and p38 MAPK Signaling in TGF-beta1-Stimulated Human Hepatic Stellate Cell Line (LX-2) via Distinct Pathways. Evid Based Complement Alternat Med, 2012, 960128.
  65. Matesic D, Sidorova T (2012). p38 MAPK activation, JNK inhibition, neoplastic growth inhibition, and increased gap junction communication in human lung carcinoma and Ras-transformed cells by 4-phenyl-3-butenoic acid. J Cell Biochem, 113, 269-81.
  66. Madhunapantula S, Robertson G (2012). Chemoprevention of melanoma. Adv Pharmacol, 65, 361-98.
  67. Mao L, Yuan L, Slakey L, et al (2010). Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res, 12107.
  68. Marshall A, Christiani D (2013). Genetic susceptibility to lung cancer--light at the end of the tunnel? Carcinogenesis, 34, 487-502.
  69. Mendoza M, Er E, et al (2010). ERK-MAP Kinase signaling in the cytoplasm. Methods Mol Biol, 661, 185-203.
  70. Merritt M, Cramer D (2010). Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark, 9, 287-305.
  71. Milone M, Pucci B, et al (2013). Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis, 4, 641.
  72. Mimura K, Shiraishi K, Mueller A, et al (2013). The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol, 191, 6261-72.
  73. Mo L, Zheng X, Huang H, et al (2007). Hyperactivation of Haras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest, 117, 314-25.
  74. Mo N, Li Z, Cao Y (2012). Curcumin inhibits TGF-$\beta$1-induced MMP-9 and invasion through ERK and Smad signaling in breast cancer MDA-MB-231 Cells. Asian Pac J Cancer Prev, 13, 5709-14.
  75. Nagini S (2012). Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol, 4, 156-69.
  76. Modugno F, Laskey R, Smith A, et al (2012). Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer, 19, 255-79.
  77. Mohammad G, Mairaj Siddiquei M, Imtiaz Nawaz M, et al (2013). The ERK1/2 inhibitor U0126 attenuates diabetesinduced upregulation of MMP-9 and biomarkers of inflammation in the retina. J Diabetes Res, 2013, 658548.
  78. Mulholland D, Kobayashi N, et al (2012). Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res, 72, 1878-89.
  79. Obata N, Tamakoshi K, et al (1997). Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res, 17, 337-42.
  80. Ochoa C, Mirabolfathinejad S, et al (2011). Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res (Phila), 4, 51-64.
  81. Park M, Zhang G, et al (2008). Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther, 7, 2633-48.
  82. Park W, Amin A, Chen Z, et al (2013). New perspectives of curcumin in cancer prevention. Cancer Prev Res, 6, 387-400.
  83. Pereira L, Igea A, Canovas B, et al (2013). Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med, 5, 1759-74.
  84. Rountree C, Mishra L, et al (2012). Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology, 55, 298-306.
  85. Philbin M, Erby L, Lee S, et al (2012) Hepatitis B and liver cancer among three Asian American sub-groups: a focus group inquiry. J Immigr Minor Health, 14, 858-68.
  86. Polo M, Arnoni M, et al (2010). Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS One, 5, 10786.
  87. Rebecca V, Sondak V, et al (2012). A brief history of melanoma: from mummies to mutations. Melanoma Res, 22, 114-22.
  88. Saldanha S, Tollefsbol T (2014). Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol, 229, 393-406.
  89. Sfanos K, Marzo A (2012). Prostate cancer and inflammation: the evidence.Histopathology, 60, 199-215.
  90. Shen M, Abate-Shen C (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev, 24, 1967-2000.
  91. Shrestha Y, Schafer E, Boehm J, et al (2012). PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene, 31, 3397-408.
  92. Slattery M, John E, et al (2013). Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One, 8, 63165.
  93. Son T, Kwon I, Hyung W (2014). Minimally invasive surgery for gastric cancer treatment: current status and future perspectives. Gut Liver, 8, 229-36.
  94. Tsao H, Chin L, Garraway L, et al (2012). Melanoma: from mutations to medicine. Genes Dev, 26, 1131-55.
  95. Sukhtankar D, Okun A, Chandramouli A, et al (2011). Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Mol Pain, 7, 81.
  96. Tanaka T, Miyazawa K, Tsukamoto T, et al (2011). Pathobiology and chemoprevention of bladder cancer. J Oncol, 2011, 528353.
  97. Thanan R, Murata M, Ma N, et al (2012). Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediators Inflamm, 2012, 165879.
  98. Walia V, Mu W, Lin J, et al (2012). Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res, 25, 155-70.
  99. Wang C, Cigliano A, Delogu S, et al (2013). Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle, 12, 1999-2010.
  100. Wang J, Kobayashi T, Floc'h N, et al (2012). B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res, 72, 4765-76.
  101. Westbrook K, Stearns V (2013). Pharmacogenomics of breast cancer therapy: an update. Pharmacol Ther, 139, 1-11.
  102. Westin S, Herzog T, et al (2013). Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs, 31, 213-29.
  103. Wilson K, Giovannucci E, et al (2012). Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl, 14, 365-74.
  104. Wu C, Zhu Z (2014). Diagnosis and evaluation of gastric cancer by positron emission tomography. World J Gastroenterol, 20, 4574-85.
  105. Zender L, Villanueva A, Tovar V, et al (2010). Cancer gene discovery in hepatocellular carcinoma. J Hepatol, 52, 921-9.
  106. Wu H, Lin W, Tsai K (2014). Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med, 16, 1.
  107. Xu Y, Li N, Xiang R, (2014). Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci, 39, 268-76.
  108. Yang Y, Kim S, Yu T, et al (2014). Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediators Inflamm, 2014, 352371.
  109. Zhang Z, Neiva K, Lingen M, et al (2010). VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ, 17, 499-512.
  110. Liang-Rui Z, Xian C, Ke-Min W (2013). Radix tetrastigma Hemsleyani flavone induces apoptosis in human lung carcinoma A549 cells by modulating the MAPK pathway. Asian Pac J Cancer Prev, 14, 5983-87.

피인용 문헌

  1. Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1 vol.40, pp.7, 2015,
  2. Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression vol.11, pp.5, 2016,
  3. Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis vol.13, pp.5, 2016,
  4. Embelin induces apoptosis of human gastric carcinoma through inhibition of p38 MAPK and NF-κB signaling pathways vol.14, pp.1, 2016,
  5. Apoptotic signal pathways and regulatory mechanisms of cancer cells induced by IL-24 vol.21, pp.6, 2016,
  6. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells vol.37, pp.7, 2016,
  7. Proliferative effects of gamma-amino butyric acid on oral squamous cell carcinoma cells are associated with mitogen-activated protein kinase signaling pathways vol.38, pp.1, 2016,
  8. Gene expression profile analysis of dbpA knockdown in colorectal cancer cells vol.40, pp.12, 2016,
  9. Phosphorylated-p38 mitogen-activated protein kinase expression is associated with clinical factors in invasive breast cancer vol.5, pp.1, 2016,
  10. The Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway as a Discovery Target in Stroke vol.59, pp.1, 2016,
  11. α-Tocopheryl succinate affects malignant cell viability, proliferation, and differentiation vol.81, pp.8, 2016,
  12. Moscatilin induces apoptosis of pancreatic cancer cells via reactive oxygen species and the JNK/SAPK pathway vol.15, pp.3, 2017,
  13. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets vol.56, pp.6, 2017,
  14. Four New Sulfated Polar Steroids from the Far Eastern Starfish Leptasterias ochotensis: Structures and Activities vol.13, pp.7, 2015,
  15. Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expression vol.13, pp.1, 2016,
  16. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer vol.18, pp.10, 2016,
  17. Genome-wide genetic analyses highlight mitogen-activated protein kinase (MAPK) signaling in the pathogenesis of endometriosis vol.32, pp.4, 2017,
  18. Effect of the BH3 Mimetic Polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma vol.9, pp.1663-9812, 2018,
  19. FGF9/FGFR2 increase cell proliferation by activating ERK1/2, Rb/E2F1, and cell cycle pathways in mouse Leydig tumor cells pp.13479032, 2018,
  20. Inhibition of ERK1/2 downregulates triglyceride and palmitic acid accumulation in cashmere goat foetal fibroblasts vol.46, pp.1, 2018,
  21. Inhibitory effects of CP on the growth of human gastric adenocarcinoma BGC-823 tumours in nude mice vol.46, pp.5, 2018,
  22. Effects of microRNA-129 and its target gene c-Fos on proliferation and apoptosis of hippocampal neurons in rats with epilepsy via the MAPK signaling pathway vol.233, pp.9, 2018,
  23. MicroRNA-374b inhibits cervical cancer cell proliferation and induces apoptosis through the p38/ERK signaling pathway by binding to JAM-2 vol.233, pp.9, 2018,
  24. Genome-wide analysis of DNA methylation in endometriosis using Illumina Human Methylation 450 K BeadChips pp.1040452X, 2019,